Literature DB >> 19728405

Evaluation of a general practice based hepatitis C virus screening intervention.

E M Anderson1, R P Mandeville, S J Hutchinson, S O Cameron, P R Mills, R Fox, S Ahmed, A Taylor, E Spence, D J Goldberg.   

Abstract

BACKGROUND: In 2003 an estimated 37,500 of Scotland's population was chronically infected with HCV; 44% were undiagnosed former injecting drug users (IDU)--a priority group for antiviral therapy. AIM: To evaluate a hepatitis C virus (HCV) screening intervention.
DESIGN: Outcome measures among two similar General Practice populations in an area of high HCV and drug use prevalence, one of which was exposed to an HCV screening intervention, were compared.
METHODS: Thirty to fifty four year old attendees of the intervention practice were opportunistically offered testing and counselling, where clinically appropriate, (November 2003-April 2004). OUTCOMES: HCV test uptake, case detection, referral and treatment administration rates.
RESULTS: Of 584 eligible attendees, 421 (72%) were offered and 117 (28%) accepted testing in the intervention practice; no testing was undertaken in the comparison practice. Prevalences of HCV antibody were 13% (15/117), 75% (3/4) and 91% (10/11) among all tested persons, current IDUs and former IDUs respectively. For 4/15 (27%) evidence of binge drinking following the receipt of their positive result, was available. Of the 11 referred to specialist care because they were HCV RNA positive, nine attended at least one appointment. Two received treatment: one had achieved a sustained viral response as of February 2008.
CONCLUSION: While non targeted HCV screening in the general practice setting can detect infected former IDU, the low diagnostic yield among non IDUs limited the effectiveness of the intervention. A more targeted approach for identifying former IDUs is recommended. Additionally, the low uptake of treatment among chronically infected persons four years after diagnosis demonstrates the difficulties in clinically managing such individuals. Strategies, including support for those with a history of problem alcohol use, to improve treatment uptake are required.

Entities:  

Mesh:

Year:  2009        PMID: 19728405     DOI: 10.1258/RSMSMJ.54.3.3

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  10 in total

1.  Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.

Authors:  Joanne E Brady; Danielle K Liffmann; Anthony Yartel; Natalie Kil; Alex D Federman; Joseph Kannry; Cynthia Jordan; Omar I Massoud; David R Nerenz; Kimberly A Brown; Bryce D Smith; Claudia Vellozzi; David B Rein
Journal:  Hepatology       Date:  2016-11-25       Impact factor: 17.425

2.  Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey.

Authors:  Angela Bechini; Abby Falla; Amena Ahmad; Irene Veldhuijzen; Sara Boccalini; Barbara Porchia; Miriam Levi
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

Review 3.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

Review 4.  Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.

Authors:  Esther Jane Aspinall; Joseph Samuel Doyle; Stephen Corson; Margaret Elena Hellard; David Hunt; David Goldberg; Tim Nguyen; Yngve Falck-Ytter; Rebecca Lynn Morgan; Bryce Smith; Mark Stoove; Stefan Zbyszko Wiktor; Sharon Hutchinson
Journal:  Eur J Epidemiol       Date:  2014-11-11       Impact factor: 8.082

Review 5.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

6.  Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.

Authors:  Azumi Ishizaki; Julie Bouscaillou; Niklas Luhmann; Stephanie Liu; Raissa Chua; Nick Walsh; Sarah Hess; Elena Ivanova; Teri Roberts; Philippa Easterbrook
Journal:  BMC Infect Dis       Date:  2017-11-01       Impact factor: 3.090

7.  Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Authors:  Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi
Journal:  J Viral Hepat       Date:  2019-08-16       Impact factor: 3.728

8.  Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C.

Authors:  A McLeod; S J Hutchinson; A Weir; S Barclay; J Schofield; C Gillespie Frew; D J Goldberg; M Heydtmann; E Wilson-Davies
Journal:  Epidemiol Infect       Date:  2022-06-27       Impact factor: 4.434

9.  Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Jared A Leff; Bruce R Schackman; Mari-Lynn Drainoni; C Robert Horsburgh; M Anita Barry; Craig Regis; Arthur Y Kim; Alison Marshall; Sheel Saxena; Peter C Smith; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 20.999

Review 10.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.